Clinical relevance of brain atrophy subtypes categorization in memory clinics
Vincent Planche, Vincent Bouteloup, Jean‐François Mangin, Bruno Dubois, Julien Delrieu, Florence Pasquier, Frédéric Blanc, Claire Paquet, Olivier Hanon, Audrey Gabelle, M. Ceccaldi, Cédric Annweiler, Pierre Krolak‐Salmon, Marie‐Odile Habert, Clara Fischer, Marie Chupin, Yannick Béjot, Olivier Godefroy, David Wallon, Mathilde Sauvée, Isabelle Bourdel‐Marchasson, Isabelle Jalenques, François Tison, Geneviève Chêne, Carole Dufouil, and the MEMENTO Study group.
Abstract
INTRODUCTION: The clinical relevance of brain atrophy subtypes categorization in non-demented persons without a priori knowledge regarding their amyloid status or clinical presentation is unknown. METHODS: A total of 2083 outpatients with either subjective cognitive complaint or mild cognitive impairment at study entry were followed during 4 years (MEMENTO cohort). Atrophy subtypes were defined using baseline magnetic resonance imaging (MRI) and previously described algorithms. RESULTS: Typical/diffuse atrophy was associated with faster cognitive decline and the highest risk of developing dementia and Alzheimer's disease (AD) over time, both in the whole analytic sample and in amyloid-positive participants. Hippocampal-sparing and limbic-predominant atrophy were also associated with incident dementia, with faster cognitive decline in the limbic predominant atrophy group. Lewy body dementia was more frequent in the hippocampal-sparing and minimal/no atrophy groups. DISCUSSION: Atrophy subtypes categorization predicted different subsequent patterns of cognitive decline and rates of conversion to distinct etiologies of dementia in persons attending memory clinics.